Navigation Links
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
Date:2/10/2011

plasms and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and China Gel Permeation Chromatography (GPC) Industry Report ... The Global and China Gel Permeation Chromatography (GPC) Industry ... current state of the global gel permeation chromatography industry ... report provides a basic overview of the industry including ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
(Date:8/21/2014)... group at the Institute for Molecular Medicine Finland ... has developed a novel "man and machine" decision ... diagnostic aid was described in PLOS One ... is based on computer vision algorithms similar to ... visualization of only the diagnostically most relevant areas. ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3
... Cepheid (NASDAQ: CPHD ) today ... Drug Administration (FDA) to market Xpert® Flu . The ... simultaneously detects and differentiates Influenza A, Influenza B, and the ... (Photo:   http://photos.prnewswire.com/prnh/20110426/LA89263 ) "With Xpert ...
... CITY, April 26, 2011 AAPC ( www.aapc.com ) ... 30, and once again lowered prices from the previous year. Prices ... "While the primary purpose of a price reduction was to ... take advantage of the significant savings," said Olga Starynskaya, coding books ...
... MALVERN, Pa., April 25, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... results for the first quarter 2011 on Monday, May 9, ... Company will also conduct a conference call that day at ... first quarter 2011.  The presentation slides to be used during ...
Cached Biology Technology:Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain 2Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain 3Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain 4AAPC Lowers Prices on Medical Coding Books, Again 2Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011 2Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011 3
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
(Date:8/21/2014)... significant reduction in smog-producing toxins in past decade, ... new study shows that while the Greater Toronto ... toxins that contribute to smog, the city continues ... pollution., Smog, which can cause or aggravate health ... is produced by a set of complex photochemical ...
(Date:8/21/2014)... SHELTON, Conn. , Aug. 21, 2014 ... on the growing mobile commerce market, announced today that ... purchase common stock to be issued in its proposed ... been approved for listing on The Nasdaq Capital Market, ... of the common stock and warrants, and will trade ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... Observation data into its Sustainable Development Report, demonstrating ... and cost-effective way to measure objectively the sustainability ... create wealth while also contributing to the long-term ... regularly issue environmental audits of their Corporate Sustainable ...
... March 25, 2008 -- Exposure to levels of radon ... to reduce the risk of developing lung cancer by as ... the March 2008 issue of the journal Health Physics. The ... of the effects of low-level radon exposure, which have detected ...
... of previously-unreported callus hairs growing in the flesh of ... have storage implications for commercial growers. To find ... Dr Mary Parker of the Institute of Food Research. ... human history and Fuji apples are particularly prized for ...
Cached Biology News:Satellites take sustainability to new heights 2Satellites take sustainability to new heights 3Satellites take sustainability to new heights 4Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds 2Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds 3Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds 4Popular apple variety harbors unusual cell growth 2
...
... Series 4000 incorporates the critical design features ... in biomarker research. The Series 4000 delivers ... converting biomarker discoveries to biomarker assays all ... is designed to fit into the research ...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
Biology Products: